To assess whether desmopressin reduces complications in patients with kidney dysfunction undergoing renal biopsy

Role of desmopressin in renal biopsy in patients with renal dysfunction (CKD-EPI with GFR < 45ml/min)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/03/041038

Enrollment

Registered

2022-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

Interventions

Intervention1: Desmopressin: Dose- 150 microgram Route- intranasal route only single dose before biopsy Control Intervention1: Normal saline: Route- Intranasally single dose before biopsy

Eligibility

Inclusion criteria

Inclusion criteria: 1. eGFR less than 45 ml per minute. 2. Those who give informed consent.

Exclusion criteria

Exclusion criteria: Pregnancy Post renal transplant patient Uncontrolled hypertension Haemoglobin Platelet count Active bleeding Evidence of active urinary tract infection Diagnosis of a congenital abnormality of kidneys or urinary tract

Design outcomes

Primary

Measure	Time frame
Major bleed requiring blood transfusion Major bleed requiring intervention Major bleed requiring nephrectomy Major bleed leading to mortality Timepoint: Hb estimation at 6-8 hours USG at 6-8 hours	—

Secondary

Measure	Time frame
Haematuria Haematoma 5 cm Bleed not requiring blood transfusion/intervention Various side effects of drug (like hyponatremia)Timepoint: at 6-8 hours	—

Countries

India

Contacts

Public ContactDr Sandep Bansal

PGIMER Chandigarh

drmanishrathi@gmail.com9216721287

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026